DNLI - Denali Therapeutics Inc.
18.21 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 18.40 |
| Open | 18.52 |
| Bid | 18.00 x 1100 |
| Ask | 18.21 x 1200 |
| Day's Range | 18.10 - 18.92 |
| 52 Week Range | 13.78 - 28.86 |
| Volume | 286,608 |
| Avg. Volume | 292,400 |
| Market Cap | 1.745B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings Date | Aug 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.33 |
- GlobeNewswire
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson’s disease, and the launch of its Engage Parkinson’s website. “Based on data generated from our prior study in healthy volunteer subjects, we are excited to evaluate DNL151 in Parkinson’s disease patients,” said Carole Ho, M.D., CMO.
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -32.61% and -7.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- GlobeNewswire
Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study. Denali will receive a $10 million clinical milestone payment from Sanofi. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing of DNL758, a peripherally restricted small molecule inhibitor of RIPK1, in a Phase 1 healthy volunteer study.
- Zacks
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Denali...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
- Zacks
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
- GlobeNewswire
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that the FDA granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation for Denali’s DNL310 program, which Denali is developing for patients with mucopolysaccharidosis II (“MPS II” or Hunter Syndrome). DNL310, or ETV:IDS, is a recombinant form of the iduronate 2-sulfatase (“IDS”) enzyme engineered to cross the blood-brain barrier (“BBB”) using Denali’s proprietary ETV technology.
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- Zacks
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- American City Business Journals
Controversial Alzheimer's Disease theory could pinpoint new drug targets
Some scientists believe Alzheimer's is a prions-like disease but is not a prions disease as identified by Nobel Prize-winning UCSF researcher Dr. Stanley Prusiner.
- Insider Monkey
Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of December 31. The results of that effort will be put on display in this article, as […]
- American City Business Journals
Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.
- Motley Fool
3 Biotech Stocks That Doubled After Hitting Bottom in 2018
Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.
- Simply Wall St.
Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boo...
- Zacks
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 4050.00% and 1191.24%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., March 12, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- GlobeNewswire
New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
“We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS penetration, and target engagement, at the studied doses.” said Carole Ho, M.D., Chief Medical Officer of Denali. “Similar to our previously announced Phase 1b study in ALS, the primary purpose of this Phase 1b study is to gain additional safety and biomarker data in patients with Alzheimer’s disease to support dose selection.
- American City Business Journals
Genentech kills big drug study in early Alzheimer's patients
Genentech's Alzheimer's-fighting drug failed two late-stage studies, but other Bay Area companies are continuing with different approaches to the memory-stealing disease.
- GlobeNewswire
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
“Based on Phase 1 data in healthy volunteer subjects demonstrating DNL747’s excellent CNS penetration, safety profile, and ability to inhibit the RIPK1 pathway, we are excited to evaluate DNL747 in ALS patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “The primary purpose of this Phase 1b study is to gain additional safety and biomarker data in ALS patients to support dose selection.
